Job Board

Job Seekers, Welcome to AABB CareerLink
Search Filters
Use this area to filter your search results. Each filter option allows for multiple selections.
Search Results: 830 Jobs
Save Agent
Loading... Please wait.
Cerus Corporation

Concord, California

LifeSouth Community Blood Centers Logo
LifeSouth Community Blood Centers

Stone Mountain, Georgia

NEW! NEW!
LifeSouth Community Blood Centers Logo
LifeSouth Community Blood Centers

Stone Mountain, Georgia

NEW! NEW!
St Jude Research Children's Hospital

Memphis, Tennessee

NEW! NEW!
WakeMed Health & Hospitals Logo
WakeMed Health & Hospitals

Raleigh, North Carolina

NEW! NEW!
We Are Blood

Austin , Texas

Prisma Health Baptist Hospital

Columbia, South Carolina

Prisma Health Richland Hospital

Columbia, South Carolina

Einstein Healthcare Network

Philadelphia, Pennsylvania

Johns Hopkins University Logo
Johns Hopkins University

Baltimore, Maryland

AABB Logo
AABB

Nationwide

Boston Children's Hospital Logo
Boston Children's Hospital

Boston, Massachusetts

Boston Children's Hospital Logo
Boston Children's Hospital

Boston, Massachusetts

Cerus Corporation

Concord, California

Inova Health System Logo
Inova Health System

Falls Church, Virginia

Food and Drug Administration, Center for Biologics Evaluation and Research

Silver Spring, Maryland

Closing Soon! Closing Soon!
AABB Logo
AABB

Bethesda, Maryland

Boston Children's Hospital Logo
Boston Children's Hospital

Boston, Massachusetts

Closing Soon! Closing Soon!
Loading... Please wait.
Job Saved Save Job
Sr. Manager / Associate Director, Platelet Biology
Cerus Corporation
Details

Posted: 26-Aug-21

Location: Concord, California

Type: Full Time

Preferred Education: Doctorate

Categories:

Manager
Email Print

About Cerus Corporation
Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action enables INTERCEPT treatment to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in the United States, Europe, Russia, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is in clinical development.
Connections working at Cerus Corporation
Loading. Please wait.
Powered By Naylor Association Solutions